XASXAVE
Market cap5mUSD
Jan 02, Last price
0.00AUD
1D
0.00%
1Q
50.00%
Jan 2017
-89.41%
Name
Avecho Biotechnology Ltd
Chart & Performance
P/E
—
P/S
20.08
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
7.59%
Rev. gr., 5y
-19.42%
Revenues
474k
-58.07%
Net income
-3m
L+46.71%
CFO
-3m
L+90.96%
Dividend
May 14, 19970.0087774011 AUD/sh
Earnings
Feb 26, 2025
Profile
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutrition industries. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It also provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company has a collaboration with Lambert Initiative at the University of Sydney to conduct a study to examine whether topically applied cannabidiol can provide relief from symptoms of osteoarthritis. It serves customers in Australia, Switzerland, India, and internationally. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 and is based in Clayton, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 474 -58.07% | 1,129 42.30% | |||||||
Cost of revenue | 5,063 | 4,193 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,589) | (3,064) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (1,076) | (623) | |||||||
Tax Rate | |||||||||
NOPAT | (3,514) | (2,441) | |||||||
Net income | (3,437) 46.71% | (2,342) -31.43% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 8,004 | ||||||||
BB yield | -100.82% | ||||||||
| Debt | |||||||||
Debt current | 77 | 71 | |||||||
Long-term debt | 273 | 350 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (5,154) | (1,047) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (3,180) | (1,665) | |||||||
CAPEX | 5 | (53) | |||||||
Cash from investing activities | (53) | ||||||||
Cash from financing activities | 7,216 | (78) | |||||||
FCF | (3,386) | (2,354) | |||||||
| Balance | |||||||||
Cash | 5,504 | 1,468 | |||||||
Long term investments | |||||||||
Excess cash | 5,481 | 1,412 | |||||||
Stockholders' equity | 6,378 | 2,425 | |||||||
Invested Capital | 1,072 | 1,259 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 2,268,084 | 1,837,785 | |||||||
Price | 0.00 -76.67% | 0.02 0.00% | |||||||
Market cap | 7,938 -71.20% | 27,567 1.97% | |||||||
EV | 2,784 | 26,520 | |||||||
EBITDA | (4,410) | (2,834) | |||||||
EV/EBITDA | |||||||||
Interest | 15 | 6 | |||||||
Interest/NOPBT | |||||||||